Recent advances in the characterization of amorphous pharmaceuticals by X-ray diffractometry

Advanced Drug Delivery Reviews

Volumn 100, Issue , 2016, Pages 183-193

  Thakral, Seema ^a,b   Terban, Maxwell W ^c   Thakral, Naveen K ^a,d   Suryanarayanan, Raj ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Lilly Corporate Center ^*  (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Amorphous; Crystallization; Solid dispersion; Total scattering pair distribution function; X ray diffractometry

Indexed keywords

BIOCHEMISTRY; CRYSTALLIZATION; DISTRIBUTION FUNCTIONS; NANOCRYSTALLINE MATERIALS; NANOCRYSTALS; X RAY DIFFRACTION; X RAY DIFFRACTION ANALYSIS;

AMORPHOUS AND NANOCRYSTALLINE MATERIALS; ORAL BIOAVAILABILITIES; PAIR DISTRIBUTION FUNCTIONS; PHARMACEUTICAL SYSTEMS; POORLY WATER-SOLUBLE DRUGS; SOLID DISPERSION; STRUCTURAL INSIGHTS; X-RAY POWDER DIFFRACTOMETRY;

AMORPHOUS MATERIALS;

CHEMICAL INTERACTION; COVALENT BOND; CRYSTALLIZATION; DISPERSION; HYDROGEN BOND; IMAGING AND DISPLAY; MEASUREMENT ACCURACY; MOLECULAR STABILITY; PRIORITY JOURNAL; REVIEW; TWO DIMENSIONAL IMAGING; VAN DER WAALS INTERACTION; WATER CONTENT; WATER VAPOR; X RAY DIFFRACTION; BIOAVAILABILITY; SOLUBILITY;

DRUG; EXCIPIENT;

BIOLOGICAL AVAILABILITY; CRYSTALLIZATION; EXCIPIENTS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; X-RAY DIFFRACTION;

EID: 84953410266     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.12.013     Document Type: Review

References (87)

1. Shah N., Sandhu H., Choi D.S., Chokshi H., Malick A.W. Amorphous solid dispersions. Theory and Practice 2014, Springer, New York.
2. Schachtschneider T.P. Phase transformations and stabilization of metastable states of molecular crystals under mechanical activation. Solid State Ionics 1997, 101:851-856.
3. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
4. Babu N.J., Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst. Growth Des. 2011, 11:2662-2679.
5. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharm. Res. 2000, 17:397-404.
6. Murdande S.B., Pikal M.J., Shanker R.M., Bogner R.H. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm. Res. 2010, 27:2704-2714.
7. Vasconcelos T., Sarmento B., Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 2007, 12:1068-1075.
8. Zografi G., Newman A. Introduction to amorphous solid dispersions. Pharmaceutical Amorphous Solid Dispersions 2015, 1-42. John Wiley & Sons, New Jersey. A. Newman (Ed.).
9. Sheen P.C., Kim S.I., Petillo J.J., Serajuddin A. Bioavailability of a poorly water-soluble drug from tablet and solid dispersion in humans. J. Pharm. Sci. 1991, 80:712-714.
10. Kennedy M., Hu J., Gao P., Li L., Ali-Reynolds A., Chal B., Gupta V., Ma C., Mahajan N., Akrami A., Surapaneni S. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. Mol. Pharm. 2008, 5:981-993.
11. Kawabata Y., Wada K., Nakatani M., Yamada S., Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int. J. Pharm. 2011, 420:1-10.
12. Ke P., Qi S., Sadowski G., Ouyang D. Solid dispersion - a pragmatic method to improve the bioavailability of poorly soluble drugs. Computational Pharmaceutics 2015, 81-97. John Wiley & Sons, West Sussex. D. Ouyang, S.C. Smith (Eds.).
13. Siddiqui A., Rahman Z., Khan S.R., Awotwe-Otoo D., Khan M.A. Root cause evaluation of particulates in the lyophilized indomethacin sodium trihydrate plug for parenteral administration. Int. J. Pharm. 2014, 473:545-551.
14. Carpenter J.F., Chang B.S. Lyophilization of protein pharmaceuticals. Biopharmaceutical Manufacturing, Processing, and Preservation 1996, 199-264. Interpharm Press, Buffalo Grove, IL. K.E. Avis, V.L. Wu (Eds.).
15. Carpenter J.F., Pikal M.J., Chang B.S., Randolph T.W. Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 1997, 14:969-975.
16. Sundaramurthi P., Suryanarayanan R. Trehalose crystallization during freeze-drying: implications on lyoprotection. J. Phys. Chem. Lett. 2009, 1:510-514.
17. Sundaramurthi P., Suryanarayanan R. Calorimetry and complementary techniques to characterize frozen and freeze-dried systems. Adv. Drug Deliv. Rev. 2012, 64:384-395.
18. The United States Pharmacopeia 38/The National Formulary 33 United States Pharmacopeial Convention, Rockville, MD 2015.
19. NIST (Accessed). http://www.nist.gov/mml/mmsd/sustainable-materials/diffraction-metrology.cfm.
20. PDF-4/Organics Database 2016, International Centre for Diffraction Data, Newtown Square, Pennsylvania, USA.
21. Chieng N., Rades T., Aaltonen J. An overview of recent studies on the analysis of pharmaceutical polymorphs. J. Pharm. Biomed. Anal. 2011, 55:618-644.
22. Egami T., Billinge S.J.L. Underneath the Bragg Peaks: Structural Analysis of Complex Materials 2012, Elsevier, Amsterdam. second ed.
23. Chatterjee K., Shalaev E.Y., Suryanarayanan R. Raffinose crystallization during freeze-drying and its impact on recovery of protein activity. Pharm. Res. 2005, 22:303-309.
24. Pyne A., Chatterjee K., Suryanarayanan R. Crystalline to amorphous transition of disodium hydrogen phosphate during primary drying. Pharm. Res. 2003, 20:802-803.
25. Thakral N.K., Mohapatra S., Stephenson G.A., Suryanarayanan R. Compression-induced crystallization of amorphous indomethacin in tablets: characterization of spatial heterogeneity by two-dimensional X-ray diffractometry. Mol. Pharm. 2015, 12:253-263.
26. Thakral N.K., Ragoonanan V., Suryanarayanan R. Quantification, mechanism, and mitigation of active ingredient phase transformation in tablets. Mol. Pharm. 2013, 10:3128-3136.
27. Koivisto M., Heinänen P., Tanninen V.P., Lehto V.P. Depth profiling of compression-induced disorders and polymorphic transition on tablet surfaces with grazing incidence X-ray diffraction. Pharm. Res. 2006, 23:813-820.
28. He B.B. Two-dimensional X-ray Diffraction 2009, Wiley, Hoboken, NJ.
29. Karmwar P., Graeser K., Gordon K.C., Strachan C.J., Rades T. Investigation of properties and recrystallization behavior of amorphous indomethacin samples prepared by different methods. Int. J. Pharm. 2011, 417:94-100.
30. N.K. Thakral, R. Suryanarayanan, (2015) unpublished data.
31. Surana R., Pyne A., Suryanarayanan R. Effect of preparation method on physical properties of amorphous trehalose. Pharm. Res. 2004, 21:1167-1176.
32. Bhardwaj S.P., Suryanarayanan R. Molecular mobility as an effective predictor of the physical stability of amorphous trehalose. Mol. Pharm. 2012, 9:3209-3217.
33. Teng J., Bates S., Engers D.A., Leach K., Schields P., Yang Y. Effect of water vapor sorption on local structure of poly (vinylpyrrolidone). J. Pharm. Sci. 2010, 99:3815-3825.
34. Billinge S.J.L. Atomic pair distribution function: a revolution in the characterization of nanostructured pharmaceuticals. Nanomedicine 2015, 10:2473-2475.
35. Bates S., Zografi G., Engers D., Morris K., Crowley K., Newman A. Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns. Pharm. Res. 2006, 23:2333-2349.
36. Billinge S.J.L., Levin I. The problem with determining atomic structure at the nanoscale. Science 2007, 316:561-565.
37. Prill D., Juhás P., Schmidt M.U., Billinge S.J.L. Modeling pair distribution functions (PDFs) of organic compounds: describing both intra- and intermolecular correlation functions in calculated PDFs. J. Appl. Crystallogr. 2015, 48:171-178.
38. Young C.A., Goodwin A.L. Applications of pair distribution function methods to contemporary problems in materials chemistry. J. Mater. Chem. 2011, 21:6464-6476.
39. Dykhne T., Taylor R., Florence A., Billinge S.J.L. Data requirements for the reliable use of atomic pair distribution functions in amorphous pharmaceutical fingerprinting. Pharm. Res. 2011, 28:1041-1048.
40. Reiss C.A., Kharchenko A., Gateshki M. On the use of laboratory X-ray diffraction equipment for pair distribution function (PDF) studies. Z. Krist. 2012, 227:257-261.
41. Chupas P.J., Qiu X., Hanson J.C., Lee P.L., Grey C.P., Billinge S.J.L. Rapid acquisition pair distribution function analysis (RA-PDF). J. Appl. Crystallogr. 2003, 36:1342-1347.
42. Abeykoon M., Malliakas C.D., Juhás P., Božin E.S., Kanatzidis M.G., Billinge S.J.L. Quantitative nanostructure characterization using atomic pair distribution functions obtained from laboratory electron microscopes. Z. Krist. 2012, 227:248-256.
43. Gorelik T.E., Schmidt M.U., Kolb U., Billinge S.J.L. Total-scattering pair-distribution function of organic material from powder electron diffraction data. Microsc. Microanal. 2015, 21:459-471.
44. M. T. Terban, S.J.L. Billinge, (2015) unpublished data.
45. Benmore C.J., Weber J.K.R., Tailor A.N., Cherry B.R., Yarger J.L., Mou Q., Weber W., Neuefeind J., Byrn S.R. Structural characterization and aging of glassy pharmaceuticals made using acoustic levitation. J. Pharm. Sci. 2013, 102:1290-1300.
46. Billinge S.J.L., Dykhne T., Juhás P., Božin E., Taylor R., Florence A.J., Shankland K. Characterization of amorphous and nanocrystalline molecular materials by total scattering. Cryst. Eng. Comm. 2010, 12:1366-1368.
47. Newman A., Engers D., Bates S., Ivanisevic I., Kelly R.C., Zografi G. Characterization of amorphous API: polymer mixtures using X-ray powder diffraction. J. Pharm. Sci. 2008, 97:4840-4856.
48. Moore M.D., Shi Z., Wildfong P.L.D. Structural interpretation in composite systems using powder X-ray diffraction: applications of error propagation to the pair distribution function. Pharm. Res. 2010, 27:2624-2632.
49. Ivanisevic I., Bates S., Chen P. Novel methods for the assessment of miscibility of amorphous drug-polymer dispersions. J. Pharm. Sci. 2009, 98:3373-3386.
50. Rumondor A.C.F., Ivanisevic I., Bates S., Alonzo D.E., Taylor L.S. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm. Res. 2009, 26:2523-2534.
51. Padilla A.M., Ivanisevic I., Yang Y., Engers D., Bogner R.H., Pikal M.J. The study of phase separation in amorphous freeze-dried systems. Part I: Raman mapping and computational analysis of XRPD data in model polymer systems. J. Pharm. Sci. 2011, 100:206-222.
52. Willart J.F., Descamps M. Solid state amorphization of pharmaceuticals. Mol. Pharm. 2008, 5:905-920.
53. Willart J.F., Durand M., Briggner L.E., Marx A., Danède F., Descamps M. Solid-state amorphization of linaprazan by mechanical milling and evidence of polymorphism. J. Pharm. Sci. 2013, 102:2214-2220.
54. Saleki-Gerhardt A., Ahlneck C., Zografi G. Assessment of disorder in crystalline solids. Int. J. Pharm. 1994, 101:237-247.
55. Willart J.F., Carpenter L., Danède F., Descamps M. Solid-state vitrification of crystalline griseofulvin by mechanical milling. J. Pharm. Sci. 2012, 101:1570-1577.
56. Blanco M., Alcalá M., González J.M., Torras E. Near infrared spectroscopy in the study of polymorphic transformations. Anal. Chim. Acta 2006, 567:262-268.
57. Koradia V., Mikko T., De Diego H.L., Ringkjøbing-Elema M., Møller-Sonnergaard J., Salonen J., Lehto V.-P., Rantanen J. Investigation of solid phase composition on tablet surfaces by grazing incidence X-ray diffraction. Pharm. Res. 2012, 29:134-144.
58. Imamura K., Nomura M., Tanaka K., Kataoka N., Oshitani J., Imanaka H., Nakanishi K. Impacts of compression on crystallization behavior of freeze-dried amorphous sucrose. J. Pharm. Sci. 2010, 99:1452-1463.
59. Leane M.M., Sinclair W., Qian F., Haddadin R., Brown A., Tobyn M., Dennis A.B. Formulation and process design for a solid dosage form containing a spray-dried amorphous dispersion of ibipinabant. Pharm. Dev. Technol. 2013, 18:359-366.
60. Joshi A.B., Patel S., Kaushal A.M., Bansal A.K. Compaction studies of alternate solid forms of celecoxib. Adv. Powder Technol. 2010, 21:452-460.
61. Thakral N.K., Yamada H., Stephenson G.A., Suryanarayanan R. Spatial distribution of trehalose dihydrate crystallization in tablets by X-ray diffractometry. Mol. Pharm. 2015, 12:3766-3775.
62. Yoshioka M., Hancock B.C., Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J. Pharm. Sci. 1994, 83:1700-1705.
63. Hermans P.H., Weidinger A. Quantitative X-ray investigation on the crystallinity of cellulose fibers. A background analysis. J. Appl. Phys. 1948, 19:491-506.
64. Hermans P.H., Weidinger A. Quantitative investigation of X-ray diffraction by amorphous polymers and some other noncrystalline substances. J. Polym. Sci. 1950, 5:269-281.
65. Chen X., Bates S., Morris K.R. Quantifying amorphous content of lactose using parallel beam X-ray powder diffraction and whole pattern fitting. J. Pharm. Biomed. Anal. 2001, 26:63-72.
66. Nunes C., Mahendrasingam A., Suryanarayanan R. Quantification of crystallinity in substantially amorphous materials by synchrotron X-ray powder diffractometry. Pharm. Res. 2005, 22:1942-1953.
67. Surana R., Suryanarayanan R. Quantitation of crystallinity in substantially amorphous pharmaceuticals and study of crystallization kinetics by X-ray powder diffractometry. Powder Diffract. 2000, 15:2-6.
68. Kothari K., Ragoonanan V., Suryanarayanan R. Influence of molecular mobility on the physical stability of amorphous pharmaceuticals in the supercooled and glassy states. Mol. Pharm. 2014, 11:3048-3055.
69. Davis T., Johnson M., Billinge S.J.L. Towards phase quantification at the nanoscale using the total scattering pair distribution function (TSPDF) method: recrystallization of cryomilled sulfamerazine. Cryst. Growth Des. 2013, 13:4239-4244.
70. Terban M.W., Cheung E.Y., Krolikowski P., Billinge S.J.L. Recrystallization, phase composition, and local structure of amorphous lactose from the total scattering pair distribution function. Cryst. Growth Des. 2015, 10.1021/acs.cgd.5b01100.
71. Qian F., Huang J., Hussain M.A. Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J. Pharm. Sci. 2010, 99:2941-2947.
72. Rumondor A.C., Stanford L.A., Taylor L.S. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm. Res. 2009, 26:2599-2606.
73. Newman A., Knipp G., Zografi G. Assessing the performance of amorphous solid dispersions. J. Pharm. Sci. 2012, 101:1355-1377.
74. Rumondor A.C., Taylor L.S. Application of partial least-squares (PLS) modeling in quantifying drug crystallinity in amorphous solid dispersions. Int. J. Pharm. 2010, 398:155-160.
75. Siddiqui A., Rahman Z., Bykadi S., Khan M.A. Chemometric methods for the quantification of crystalline tacrolimus in solid dispersion by powder X-ray diffractrometry. J. Pharm. Sci. 2014, 103:2819-2828.
76. Rahman Z., Bykadi S., Siddiqui A., Khan M.A. Comparison of X-ray powder diffraction and solid-state nuclear magnetic resonance in estimating crystalline fraction of tacrolimus in sustained-release amorphous solid dispersion and development of discriminating dissolution method. J. Pharm. Sci. 2015, 104:1777-1786.
77. Newman J.A., Schmitt P.D., Toth S.J., Deng F., Zhang S., Simpson G.J. Parts per million powder X-ray diffraction. Anal. Chem. 2015, published online.
78. Wegiel L.A., Mauer L.J., Edgar K.J., Taylor L.S. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage - impact of different polymers. J. Pharm. Sci. 2013, 102:171-184.
79. Kothari K., Ragoonanan V., Suryanarayanan R. The role of drug-polymer hydrogen bonding interactions on the molecular mobility and physical stability of nifedipine solid dispersions. Mol. Pharm. 2015, 12:162-170.
80. Mistry P., Mohapatra S., Gopinath T., Vogt F.G., Suryanarayanan R. Role of the strength of drug-polymer interactions on the molecular mobility and crystallization inhibition in ketoconazole solid dispersions. Mol. Pharm. 2015, 12:3339-3350.
81. Greco S., Authelin J.R., Leveder C., Segalini A. A practical method to predict physical stability of amorphous solid dispersions. Pharm. Res. 2012, 29:2792-2805.
82. Van Eerdenbrugh B., Raina S., Hsieh Y.L., Augustijns P., Taylor L.S. Classification of the crystallization behavior of amorphous active pharmaceutical ingredients in aqueous environments. Pharm. Res. 2014, 31:969-982.
83. Alonzo D.E., Zhang G.G., Zhou D., Gao Y., Taylor L.S. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm. Res. 2010, 27:608-618.
84. Jacques S.D.M., Michiel M.D., Kimber S.A.J., Yang X., Cernik R.J., Beale A.M., Billinge S.J.L. Pair distribution function computed tomography. Nat. Commun. 2013, 4:2536.
85. Jensen K.M.Ø., Yang X., Laved J.V., Zeir W.G., See K.A., Di Michiel M., Melot B.C., Corr S.A., Billinge S.J.L. X-ray diffraction computed tomography for structural analysis of electrode materials in batteries. J. Electrochem. Soc. 2015, 162:A1310-A1314.
86. Jensen K.M.Ø., Blichfeld A.B., Bauers S.R., Wood S.R., Dooryhée E., Johnson D.C., Iversen B.B., Billinge S.J.L. Demonstration of thin film pair distribution function analysis (tfPDF) for the study of local structure in amorphous and crystalline thin films. IUCrJ. 2015, published online.
87. Ng Y.C., Yang Z., McAuley W.J., Qi S. Stabilization of amorphous drugs under high humidity using pharmaceutical thin films. Eur. J. Pharm. Biopharm. 2013, 84:555-565.